{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:15:19Z","timestamp":1794568519861,"version":"4.9.1"},"reference-count":50,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Rapid diagnostics can drive antimicrobial stewardship strategies and allow clinicians to develop more precise and individualized treatment pathways. Q-linea ASTar is an FDA-cleared\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      diagnostic for rapid phenotypic antimicrobial susceptibility testing (AST) system in patients with gram-negative blood stream infections (BSIs). In this study, we report the performance of Q-linea ASTar compared with the standard of care (SOC) method, MicroScan. A total of 83 clinical samples were enrolled in the study. The overall categorical agreement (CA) after discrepancy analysis was 94.6%, with 0.5% very major errors (1\/218; VME) and 0.7% major errors (9\/1,282; ME). In addition to assay performance, we assessed the hypothetical impact of rapid AST on antimicrobial stewardship prescribing practices for 57 patients with gram-negative BSI. Twenty-nine patients (50.9%) had a potential impact from ASTar on antimicrobial management, including 27 instances of de-escalation. For patients with potential impact, targeted therapy could be achieved in 22.7 h (IQR 21.0-26.3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) from blood culture collection, with a median time savings of 41.8 h compared with SOC. In summary, Q-linea ASTar performed favorably to SOC methods for AST and demonstrates the potential for shorter time to targeted antibiotic therapy in patients with gram-negative BSI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>IMPORTANCE<\/jats:title>\n                    <jats:p>Rapid phenotypic antimicrobial susceptibility testing (AST) has the potential to have significant impacts on antimicrobial stewardship and the treatment of blood stream infections (BSIs). There is a gap in information regarding the optimal utilization and clinical impact of rapid AST. This study evaluates new technology in the field of rapid AST, including its performance compared with standard of care practices and its potential impacts on the use of antibiotics in patients with gram-negative BSIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.03917-25","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:01:02Z","timestamp":1781524862000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Q-linea ASTar rapid phenotypic antimicrobial susceptibility testing and potential impact in patients with gram-negative bloodstream infections"],"prefix":"10.1128","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4066-8029","authenticated-orcid":true,"given":"Elizabeth M.","family":"Garrett","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Division of Clinical Pathology, Penn State College of Medicine","place":["Hershey, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Lesher","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01h22ap11","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy Services, Penn State Health Milton S. Hershey Medical Center","place":["Hershey, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenii","family":"Kovtunov","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Division of Clinical Pathology, Penn State College of Medicine","place":["Hershey, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory M.","family":"Hale","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01h22ap11","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy Services, Penn State Health Milton S. Hershey Medical Center","place":["Hershey, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Division of Clinical Pathology, Penn State College of Medicine","place":["Hershey, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6167-198X","authenticated-orcid":true,"given":"April M.","family":"Bobenchik","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Division of Clinical Pathology, Penn State College of Medicine","place":["Hershey, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12195"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166527"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2710.204826"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-19"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07810-8"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.760-766.2005"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000217961.75225.E9"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac089"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2899"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad413"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.25252"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.1938"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2201"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.03.024"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharma2040025"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae591"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae253"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01796-22"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07772-x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ447"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01329-17"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw118"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13080786"},{"key":"e_1_3_4_25_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2025. EUCAST rapid antimicrobial susceptibility testing (RAST) directly from positive blood culture bottles version 6.0"},{"key":"e_1_3_4_26_2","volume-title":"CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2025","unstructured":"Clinical and Laboratory Standards Institute. 2025. Performance standards for antimicrobial susceptibility testing. In CLSI supplement M100, 35th ed. Clinical and Laboratory Standards Institute (CLSI).","edition":"35"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00098-22"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00922-24"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05046-3"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae477"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz406"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa528"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01525-22"},{"key":"e_1_3_4_34_2","unstructured":"MicroScan gram negative procedural manual LabPro \u2265V4.42 PU-08 panel C42772-AB. 2019. Beckman Coulter"},{"key":"e_1_3_4_35_2","volume-title":"CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2022","unstructured":"Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing. In CLSI supplement M100, 32rd ed. Clinical and Laboratory Standards Institute (CLSI).","edition":"32"},{"key":"e_1_3_4_36_2","unstructured":"Clinical and Laboratory Standards Institute. 2024. Performance standards for antimicrobial susceptibility testing. In 34th ed. Clinical and Laboratory Standards Institute (CLSI)."},{"key":"e_1_3_4_37_2","unstructured":"Q-linea. 2024. ASTar BC G\u2212 Kit Instructions for use version 6"},{"key":"e_1_3_4_38_2","volume-title":"M07","author":"Clinical and Laboratory Standards Institute","year":"2024","unstructured":"Clinical and Laboratory Standards Institute. 2024. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In M07, 12th ed. Clinical and Laboratory Standards Institute (CLSI).","edition":"12"},{"key":"e_1_3_4_39_2","volume-title":"CLSI supplement M23","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Development of in vitro susceptibility testing criteria and quality control parameters. In CLSI supplement M23, 5th ed. Clinical and Laboratory Standards Institute.","edition":"5"},{"key":"e_1_3_4_40_2","unstructured":"ISO 20776-2:2021(E) Clinical laboratory testing and in vitro diagnostic test systems \u2014 Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices \u2014 Part 2: evaluation of performance of antimicrobial susceptibility test devices against reference broth microdilution. 2021"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae280"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00549-23"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-023-00619-6"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00122-22"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab921"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae282"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.03.038"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03737-2"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa427"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw649"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02364-20"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03917-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03917-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:58:19Z","timestamp":1788224299000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.03917-25"}},"subtitle":[],"editor":[{"given":"Kessendri","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,7]]}},"alternative-id":["10.1128\/spectrum.03917-25"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.03917-25","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2025-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03917-25"}}